Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lang Qingata for Non-alcoholic Steatohepatitis
NCT06193629Recruiting
- Start
- Mar 2024
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in Nonalcoholic steatohepatitis (NASH) comparing Lang Qingata with Placebo (2 arms). Primary endpoint: Total effective rate of clinical effect at 2 months. Started Mar 2024; status: recruiting.
02
Drugs
Lang Qingata
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT06193629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06193629.